With a capacity to process more than 1,000 tests in 24 hours, the system can offer initial results in about three hours. Credit: Business Wire / Hologic.

Hologic has secured 510(k) clearance from the US Food and Drug Administration (FDA) for its fully automated and high-throughput Panther Fusion SARS-CoV-2/Flu A/B/RSV assay.

The molecular diagnostic test is intended for the detection and differentiation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A (flu A), influenza B (flu B) and respiratory syncytial virus (RSV). These four respiratory viruses have similar clinical symptoms.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Hologic diagnostic solutions president Dr Jennifer Schneiders said: “While we are out of the respiratory virus season this year, accurate viral diagnosis remains a high priority for clinicians for the upcoming respiratory season and we are committed to advancing Covid and respiratory diagnostics on our Panther Fusion system.

“This test will be a critical tool to help determine which respiratory virus or coinfection patients have so that providers can better inform the best course of treatment.”

With a capacity to process more than 1,000 tests in 24 hours, the system can offer initial results in about three hours.

The company is launching the new assay with the RespDirect collection kit, which allows laboratories to load samples directly onto the Panther Fusion system.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It helps eliminate uncapping and specimen transfer steps, save time and reduce errors, injuries and viral exposure risks.

The US Department of Health and Human Services, along with the Biomedical Advanced Research and Development Authority and the Administration for Strategic Preparedness and Response, provided financial support for this project.